Christine Wood
Primary Care · Huntsville, ALNPI 1396218707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 268 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$974
- Astellas Pharma US Inc$719
- AbbVie$445
- Procept Biorobotics Corporation$338
- Urovant Sciences Inc$214
- Dendreon Pharmaceuticals LLC$212
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,965100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 51 | $974 |
| Astellas Pharma US Inc | 59 | $719 |
| AbbVie | 28 | $445 |
| Procept Biorobotics Corporation | 7 | $338 |
| Urovant Sciences Inc | 13 | $214 |
| Dendreon Pharmaceuticals LLC | 6 | $212 |
| Boston Scientific | 8 | $188 |
| Myriad Genetic Laboratories, Inc. | 11 | $181 |
| Urogen Pharma, Inc. | 6 | $142 |
| Medtronic | 7 | $138 |
| Endo Pharmaceuticals Inc. | 8 | $132 |
| Endo USA, Inc. | 6 | $119 |
| Tolmar, Inc. | 5 | $118 |
| Pfizer | 6 | $111 |
| Antares Pharma, Inc. | 5 | $95 |
| ABC Home Medical Supply, Inc. | 1 | $92 |
| Olympus America Inc. | 4 | $75 |
| Immunitybio, Inc. | 3 | $64 |
| Rochester Medical Corporation | 3 | $60 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| Coloplast | 2 | $50 |
| Mission Pharmacal Company | 2 | $38 |
| Accord Healthcare, Inc. | 2 | $38 |
| Tolmar Pharmaceuticals, Inc. | 2 | $38 |
| Clarus Therapeutics Inc. | 2 | $36 |
| Progenics Pharmaceuticals, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Myovant Sciences Inc. | 2 | $31 |
| Convatec Inc. | 2 | $30 |
| Blue Earth Diagnostics | 1 | $23 |
| Merck | 1 | $21 |
| Bayer | 1 | $21 |
| Telix Pharmaceuticals | 1 | $21 |
| Teleflex LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $2 |
How this compares
$4,967 in reported general payments places this provider in the 85th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 56 | $41,322 |
| GemtesaVibegron | 50 | $33,479 |
| NitrofurantoinNitrofurantoin Macrocrystal | 95 | $3,795 |
| Tamsulosin Hcl | 193 | $3,453 |
| Estradiol | 37 | $2,791 |
| Methenamine Hippurate | 33 | $2,665 |
| Trimethoprim | 26 | $1,874 |
| Solifenacin Succinate | 29 | $1,468 |
| Silodosin | 17 | $1,382 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $1,216 |
| Cephalexin | 97 | $1,077 |
| Dutasteride | 26 | $868 |
| Finasteride | 54 | $651 |
| Oxybutynin Chloride | 20 | $645 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 78 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $719 | $41,32256 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $974 | $33,47950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 primary care providers in Alabama.
Other primary care in Huntsville
- Cleo ValdezHuntsville$14K
- Allison BrownHuntsville$4K
- Meredith PolsHuntsville$3K
- Emory ColemanHuntsville$3K
- Alyson JusticeHuntsville$2K
- Emily KomaraHuntsville$2K
- Johnnie AmadiHuntsville$2K
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.